Epidemiology of Homocysteine as a Risk Factor in Diabetes

Metabolic Syndrome and Related Disorders

Volumn 1, Issue 2, 2003, Pages 105-120

  Becker, A ^a   Smulders, Y M ^a   Van Guldener, C ^a,b   Stehouwer, C D A ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2942603929     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/154041903322294434     Document Type: Review

References (103)

1. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 1993; 306: 1313–1318.
2. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetesepidemic. Nature 2001; 414:782–787.
3. Grundy SM, Howard B, Smith S Jr, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105: 2231–2239.
4. Eikelboom JW, Lonn E, Genest J Jr, et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363–375.
5. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015–2022.
6. van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost 2000; 26: 281–289.
7. Brattstrom L, Wilcken DE, Ohrvik J, et al. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98: 2520–2526.
8. Nygard O, Refsum H, Ueland PM, et al. Major life-style determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 1998; 67: 263–270.
9. Jacques PF, Bostom AG, Wilson PW, et al. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001; 73: 613–621.
10. van Guldener C, Stam F, Stehouwer CD. Homocysteine metabolism in renal failure. Kidney Int 2001; 59(Suppl 78): S234–S237.
11. Smulders YM, Rakic M, Slaats EH, et al. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999; 22: 125–132.
12. Stabler SP, Estacio R, Jeffers BW, et al. Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Metabolism 1999; 48:1096–1101.
13. Mazza A, Motti C, Nulli A, et al. Lack of association between carotid intima-media thickness and methyl-enetetrahydrofolate reductase gene polymorphism or serum homocysteine in non-insulin-dependent diabetes mellitus. Metabolism 2000; 49: 718–723.
14. Pavia C, Ferrer I, Valls C, et al. Total homocysteine in patients with type 1 diabetes. Diabetes Care 2000; 23:84–87.
15. Targher G, Bertolini L, Zenari L, et al. Cigarette smoking and plasma total homocysteine levels in young adults with type 1 diabetes. Diabetes Care 2000; 23: 524–528.
16. Emoto M, Kanda H, Shoji T, et al. Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 2001; 24: 533–538.
17. Wollesen F, Brattstrom L, Refsum H, et al. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999; 55: 1028–1035.
18. van Guldener C, Donker AJ, Jakobs C, et al. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54: 166–169.
19. Zinneman HH, Nuttall FQ, Goetz FC. Effect of endogenous insulin on human amino acid metabolism. Diabetes 1966; 15: 5–8.
20. Jacobs RL, House JD, Brosnan ME, et al. Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Diabetes 1998; 47: 1967–1970.
21. Ratnam S, Maclean KN, Jacobs RL, et al. Hormonal regulation of cystathionine beta-synthase expression in liver. J Biol Chem 2002; 277: 42912–42918.
22. Gursu MF, Baydas G, Cikim G, et al. Insulin increases homocysteine levels in a dose-dependent manner in diabetic rats. Arch Med Res 2002; 33: 305–307.
23. Dicker-Brown A, Fonseca VA, Fink LM, et al. The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-beta-synthase: studies in hepatocytes. Atherosclerosis 2001; 158:297–301.
24. Fonseca VA, Mudaliar S, Schmidt B, et al. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism 1998; 47: 686–689.
25. Giltay EJ, Hoogeveen EK, Elbers JM, et al. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. Atherosclerosis 1998; 139: 197–198.
26. De Pergola G, Pannacciulli N, Zamboni M, et al. Homocysteine plasma levels are independently associated with insulin resistance in normal weight, overweight and obese pre-menopausal women. Diabetes Nutr Metab 2001; 14: 253–258.
27. Meigs JB, Jacques PF, Selhub J, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care 2001; 24: 1403–1410.
28. Abbasi F, Facchini F, Humphreys MH, et al. Plasma homocysteine concentrations in healthy volunteers are not related to differences in insulin-mediated glucose disposal. Atherosclerosis 1999; 146: 175–178.
29. Rosolova H, Simon J, Mayer O Jr, et al. Unexpected inverse relationship between insulin resistance and serum homocysteine in healthy subjects. Physiol Res 2002; 51: 93–98.
30. Godsland IF, Rosankiewicz JR, Proudler AJ, et al. Plasma total homocysteine concentrations are unrelated to insulin sensitivity and components of the metabolic syndrome in healthy men. J Clin Endocrinol Metab 2001; 86: 719–723.
31. Buysschaert M, Dramais AS, Wallemacq PE, et al. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000; 23: 1816–1822.
32. Gallistl S, Sudi K, Mangge H, et al. Insulin is an independent correlate of plasma homocysteine levels in obese children and adolescents. Diabetes Care 2000; 23: 1348–1352.
33. Bar-On H, Kidron M, Friedlander Y, et al. Plasma total homocysteine levels in subjects with hyperinsulinemia. J Intern Med 2000; 247: 287–294.
34. Hoogeveen EK, Kostense PJ, Jager A, et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 1998; 54: 203–209.
35. Wiltshire E, Thomas DW, Baghurst P, et al. Reduced total plasma homocyst(e)ine in children and adolescents with type 1 diabetes. J Pediatr 2001; 138: 888–893.
36. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? J Intern Med 1997; 242: 389–394.
37. de Lorgeril M, Salen P, Paillard F, et al. Lipid-lowering drugs and homocysteine. Lancet 1999; 353: 209–210.
38. Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999; 354: 219–220.
39. Lipscombe J, Lewis GF, Cattran D, et al. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 2001; 55: 39–44.
40. Cenerelli S, Bonazzi P, Galeazzi R, et al. Helicobacter pylori masks differences in homocysteine plasma levels between controls and type 2 diabetic patients. Eur J Clin Invest 2002; 32: 158–162.
41. Passaro A, D'Elia K, Pareschi PL, et al. Factors influencing plasma homocysteine levels in type 2 diabetes. Diabetes Care 2000; 23: 420–421.
42. Cassone Faldetta M, Laurenti O, Desideri G, et al. L-Arginine infusion decreases plasma total homocysteine concentrations through increased nitric oxide production and decreased oxidative status in type II diabetic patients. Diabetologia 2002; 45: 1120–1127.
43. Tan KC, Chow WS, Ai VH, et al. Hyperhomocysteinemia and impaired vasomotor function in type 2 diabetes mellitus. Eur J Clin Invest 2002; 32: 328–334.
44. Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non- insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 1993; 103: 149–157.
45. Chico A, Perez A, Cordoba A, et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998; 41: 684–693.
46. Hofmann MA, Kohl B, Zumbach MS, et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998; 21: 841–848.
47. Mutus B, Rabini RA, Staffolani R, et al. Homocysteine-induced inhibition of nitric oxide production in platelets: a study on healthy and diabetic subjects. Diabetologia 2001; 44: 979–982.
48. Hultberg B, Agardh E, Andersson A, et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1991; 51: 277–282.
49. Lanfredini M, Fiorina P, Peca MG, et al. Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients. Metabolism 1998; 47:915–921.
50. Vaccaro O, Perna AF, Mancini FP, et al. Plasma homocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis 2000; 10: 297–304.
51. Robillon JF, Canivet B, Candito M, et al. Type 1 diabetes mellitus and homocyst(e)ine. Diabete Metab 1994; 20: 494–496.
52. Oishi K, Nagake Y, Yamasaki H, et al. The significance of serum homocysteine levels in diabetic patients on haemodialysis. Nephrol Dial Transplant 2000; 15:851–855.
53. Suliman ME, Stenvinkel P, Heimburger O, et al. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis 2002; 40: 480–488.
54. Al-Nozah M, Al-Daghri N, Bartlett WA, et al. Serum homocysteine concentration is related to diabetes mellitus, but not to coronary heart disease, in Saudi Arabians. Diabetes Obes Metab 2002; 4: 118–123.
55. Cronin CC, McPartlin JM, Barry DG, et al. Plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 1998; 21: 1843–1847.
56. Kark JD, Selhub J, Bostom A, et al. Plasma homocysteine and all-cause mortality in diabetes. Lancet 1999; 353: 1936–1937.
57. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyper-homocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998; 18: 133–138.
58. Chiarelli F, Pomilio M, Mohn A, et al. Homocysteine levels during fasting and after methionine loading in adolescents with diabetic retinopathy and nephropathy. J Pediatr 2000; 137: 386–392.
59. Agardh CD, Agardh E, Andersson A, et al. Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1994; 54: 637–641.
60. Ozmen B, Ozmen D, Turgan N, et al. Association between homocysteinemia and renal function in patients with type 2 diabetes mellitus. Ann Clin Lab Sci 2002; 32: 279–286.
61. Davies L, Wilmshurst EG, McElduff A, et al. The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care 2001; 24: 1805–1809.
62. Abdella N, Mojiminiyi OA, Akanji AO. Homocysteine and endogenous markers of renal function in type 2 diabetic patients without coronary heart disease. Diabetes Res Clin Pract 2000; 50: 177–185.
63. Jager A, Kostense PJ, Nijpels G, et al. Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn study. Arterioscler Thromb Vasc Biol 2001; 21: 74–81.
64. Kumagai H, Katoh S, Hirosawa K, et al. Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney Int 2002; 62: 1219–1228.
65. Hovind P, Tarnow L, Rossing P, et al. Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. Am J Kidney Dis 2001; 38: 1376–1380.
66. Samuelsson O, Lee DM, Attman PO, et al. The plasma levels of homocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression. Nephron 1999; 82: 306–311.
67. Buysschaert M, Jamart J, Dramais AS, et al. Micro-and macrovascular complications and hyperhomocysteinaemia in type 1 diabetic patients. Diabetes Metab 2001; 27: 655–659.
68. Agardh E, Hultberg B, Agardh CD. Severe retinopathy in type 1 diabetic patients is not related to the level of plasma homocysteine. Scand J Clin Lab Invest 2000; 60: 169–174.
69. Vaccaro O, Ingrosso D, Rivellese A, et al. Moderate hyperhomocysteinaemia and retinopathy in insulin-dependent diabetes. Lancet 1997; 349: 1102–1103.
70. Klein R, Klein BE, Moss SE, et al. Hypertension and retinopathy, arteriolar narrowing, and arteriovenous nicking in a population. Arch Ophthalmol 1994; 112: 92–98.
71. Stolk RP, Vingerling JR, de Jong PT, et al. Retinopathy, glucose, and insulin in an elderly population. The Rotterdam Study. Diabetes 1995; 44: 11–15.
72. Hoogeveen EK, Kostense PJ, Eysink PE, et al. Hyper-homocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med 2000; 160: 2984–2990.
73. Vinik AI, Park TS, Stansberry KB, et al. Diabetic neuropathies. Diabetologia 2000; 43: 957–973.
74. Hoogeveen EK, Kostense PJ, Valk GD, et al. Hyper-homocysteinaemia is not related to risk of distal somatic polyneuropathy: the Hoorn Study. J Intern Med 1999; 246: 561–566.
75. Ambrosch A, Dierkes J, Lobmann R, et al. Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabet Med 2001; 18: 185–192.
76. Cohen JA, Jeffers BW, Stabler S, et al. Increasing homocysteine levels and diabetic autonomic neuropathy. Auton Neurosci 2001; 87: 268–273.
77. Kaye JM, Stanton KG, McCann VJ, et al. Homocysteine, folate, methylene tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects. Clin Sci (Lond) 2002; 102: 631–637.
78. Okada E, Oida K, Tada H, et al. Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 1999; 22: 484–490.
79. Scaglione L, Gambino R, Rolfo E, et al. Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients. Eur J Clin Invest 2002; 32: 24–28.
80. Stehouwer CD, Gall MA, Hougaard P, et al. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 1999; 55: 308–314.
81. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyper-homocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn study. Circulation 2000; 101: 1506–1511.
82. Shukla N, Thompson CS, Angelini GD, et al. Homocysteine enhances impairment of endothelium-dependent relaxation and guanosine cyclic monophosphate formation in aortae from diabetic rabbits. Diabetologia 2002; 45: 1325–1331.
83. West IC. Radicals and oxidative stress in diabetes. Diabet Med 2000; 17: 171–180.
84. Jeremy J, Shukla N, Angelini G. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 2002; 164: 383.
85. Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin signaling, and glutathione has a protective effect. J Mol Endocrinol 2001; 27: 85–91.
86. Fonseca VA, Stone A, Munshi M, et al. Oxidative stress in diabetic macrovascular disease: does homocysteine play a role? South Med J 1997; 90: 903–906.
87. Becker A, Van Hinsbergh VW, Kostense PJ, et al. Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule 1, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects—the Hoorn study. Eur J Clin Invest 2000; 30: 763–770.
88. Targher G, Zenari L, Bertolini L, et al. Plasma total homocysteine levels are associated with von Willebrand factor, soluble intercellular adhesion molecule-1, and soluble tumor necrosis factor-alpha receptors in young type 1 diabetic patients without clinical evidence of macrovascular complications. Diabetes Care 2001; 24: 1496–1497.
89. Jager A, van Hinsbergh VW, Kostense PJ, et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes 2000; 49: 485–491.
90. Baliga BS, Reynolds T, Fink LM, et al. Hyperhomocysteinemia in type 2 diabetes mellitus: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine. Endocrinol Pract 2000; 6: 435–441.
91. Wiltshire EJ, Gent R, Hirte C, et al. Endothelial dysfunction relates to folate status in children and adolescents with type 1 diabetes. Diabetes 2002; 51: 2282–2286.
92. Burke AP, Fonseca V, Kolodgie F, et al. Increased serum homocysteine and sudden death resulting from coronary atherosclerosis with fibrous plaques. Arterioscler Thromb Vasc Biol 2002; 22: 1936–1941.
93. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526–1533.
94. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775–1781.
95. Kahleova R, Palyzova D, Zvara K, et al. Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypertens 2002; 15: 857–864.
96. Perna AF, Ingrosso D, De Santo NG, et al. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995; 47: 247–253.
97. Quere I, Perneger TV, Zittoun J, et al. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet 2002; 359: 747–752.
98. Loehrer F, Angst C, Brunner F, et al. Evidence for disturbed S-adenosylmethionine: S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions? Nephrol Dial Transplant 1998; 13: 656–661.
99. Lee ME, Wang H. Homocysteine and hypomethylation. A novel link to vascular disease. Trends Cardiovasc Med 1999; 9: 49–54.
100. Dayal S, Bottiglieri T, Arning E, et al. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine β-synthase-deficient mice. Circ Res 2001; 88: 1203–1209.
101. Kerins DM, Koury MJ, Capdevila A, et al. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr 2001; 74: 723–729.
102. Loehrer FM, Tschopl M, Angst CP, et al. Disturbed ratio of erythrocyte and plasma S-adenosylmethionine/S-adenosylhomocysteine in peripheral arterial occlusive disease. Atherosclerosis 2001; 154: 147–154.
103. Poirier LA, Brown AT, Fink LM, et al. Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathy. Metabolism 2001; 50: 1014–1018.